Participated · Equity · Feb 2026

Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Participated · Equity · Sep 2025

Noctrix Health is a Pleasanton, CA-based medical device company developing the Nidra Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS). Its flagship TOMAC therapy is a non-pharmacologic treatment intended to reduce symptoms of primary moderate-to-severe RLS and improve sleep quality in adults who are refractory to medications. Led by CEO and President Shri Raghunathan, the company focuses on clinically validated medical technologies to improve quality of life for patients with chronic medical conditions. Noctrix raised up to $33.5M in a financing that included both debt and equity. Backers included Blue Venture Fund and Sandbox Clinical Ventures. The company intends to use the funds to accelerate its U.S. commercial launch. Noctrix Health is a medical device company led by founder and CEO Shri Raghunathan that develops the Nidra™ Tonic Motor Activation (TOMAC) system, a non‑pharmacologic wearable intended to reduce symptoms of primary moderate‑severe Restless Legs Syndrome (RLS). The TOMAC system is designed to improve sleep quality in adults refractory to medications and is available in the US by prescription only. The company closed a $40M Series C financing to advance the therapy toward an anticipated US launch. Noctrix describes itself as committed to developing clinically validated medical technologies that improve quality of life for patients with chronic conditions. The new funding is intended to support regulatory and commercialization activities for the Nidra™ TOMAC therapy in the US.

Participated · Series A · Jan 2025

PinkDx is an early-stage company based in Daly City, California that applies advanced science and technology to address medical problems unique to women. Its lead program is a diagnostic test intended to clarify diagnoses for women who present with general symptoms that may signal a gynecologic cancer. The company aims to replace invasive diagnostic procedures, reduce delays in obtaining answers, and enable faster, more appropriate care for patients and physicians. PinkDx reports progress in discovery and development and is advancing the test toward clinical validation. The company completed an upsized Series A round totaling $45 million to support development and clinical validation toward commercialization. As part of BEVC's investment, PinkDx joined Bakar Labs, linking the company to UC Berkeley's life-science incubator and strategic resources. PinkDx is an early-stage, Daly City, CA–based company focused on positively impacting the health of women across their life journey. Led by cofounder, chairwoman and CEO Bonnie Anderson, with CSO Giulia C. Kennedy, Ph.D., and CFO/Chief Business Officer Tim McMeekan, the company applies scientific approaches to address medical problems affecting women. Its first indication targets overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. PinkDx will use the Series A proceeds to advance test development, initially focusing on gynecological cancers. The company also appointed Alison Cowan, M.D., M.S.C.R., as chief medical officer to guide clinical development; she previously led Medical Affairs at Mirvie and served as medical director for Hologic’s Diagnostics division.